Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
| Autor: | Julie Navez, Yeter Gokburun, Luigi Moretti, Jean-Luc Van Laethem, Patrizia Loi, Christelle Bouchart, Alain Hendlisz, Dirk Van Gestel, Jean Closset, Pierre Eisendrath, Maria Antonietta Bali, Thierry De Grez, Matthieu Hein, Laura Mans, Jean-Luc Engelholm |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Pancreatic ductal adenocarcinoma Stereotactic body radiation therapy business.industry medicine.medical_treatment pancreatic cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Radiation therapy Stereotactic radiotherapy Oncology Pancreatic cancer medicine stereotactic radiotherapy Radiology neoadjuvant therapy business Stereotactic body radiotherapy Neoadjuvant therapy radiotherapy RC254-282 Original Research |
| Zdroj: | Therapeutic Advances in Medical Oncology, Vol 13 (2021) Therapeutic Advances in Medical Oncology |
| ISSN: | 1758-8359 |
| Popis: | Background: Our aim was to evaluate the feasibility and safety of isotoxic high-dose (iHD) stereotactic body radiation therapy (SBRT) in a total neoadjuvant sequence for the treatment of localized pancreatic adenocarcinoma. Materials and methods: Biopsy-proven borderline resectable/locally advanced pancreatic cancer (BR/LAPC) patients were included in this observational prospective analysis from August 2017 to April 2020 without excluding tumours showing a radiological direct gastrointestinal (GI) invasion. An induction chemotherapy by modified fluorouracil, irinotecan and oxaliplatin was performed for a median of six cycles. In case of non-progression, an isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT) was delivered in 5 fractions followed by a surgical exploration. The primary endpoint was acute/late gastrointestinal grade ⩾3 toxicity. Secondary endpoints were overall survival (OS), progression-free survival (PFS) and local control (LC). Results: A total of 39 consecutive patients (21 BR and 18 LAPC) were included: 34 patients (87.2%, 18 BR and 16 LAPC) completed the planned neoadjuvant sequence. After iHD-SBRT, 19 patients [55.9% overall, 13/18 BR (72.2%) and 6/16 LAPC (37.5%)] underwent an oncological resection among the 25 patients surgically explored (73.5%). The median follow up was 18.2 months. The rates of acute and late GI grade 3 toxicity were, respectively, 2.9% and 4.2%. The median OS and PFS from diagnosis were, respectively, 24.5 and 15.6 months. The resected patients had improved median OS and PFS in comparison with the non-resected patients (OS: 32.3 versus 18.2 months, p = 0.02; PFS: 24.1 versus 7.1 months, p Conclusions: iHD-SBRT displays an excellent toxicity profile, also for potentially high-risk patients with radiological direct GI invasion at diagnosis and can be easily integrated in a total neoadjuvant strategy. The oncological outcomes are promising and emphasise the need for further exploration of iHD-SBRT in phase II/III trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|